Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
37
PMVP Quote, Financials, Valuation and Earnings
Last price:
$1.08
Seasonality move
:
-33.08%
Day range:
$1.05 - $1.09
52-week range:
$0.81 - $1.84
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.47x
Volume:
56K
Avg. volume:
271.6K
1-year change:
-21.9%
Market cap:
$56.9M
Revenue:
--
EPS (TTM):
-$1.58
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PMVP
PMV Pharmaceuticals, Inc.
|
-- | -$0.41 | -- | -8.56% | $7.60 |
|
ACRS
Aclaris Therapeutics, Inc.
|
$2.1M | -$0.14 | 27.15% | -8.22% | $8.00 |
|
AVIR
Atea Pharmaceuticals, Inc.
|
-- | -$0.49 | -- | -31.71% | $7.67 |
|
ORMP
Oramed Pharmaceuticals, Inc.
|
-- | -$0.07 | -- | -75% | $3.25 |
|
PBYI
Puma Biotechnology, Inc.
|
$68.6M | $0.23 | 16.12% | -41.13% | $5.00 |
|
TIL
Instil Bio, Inc.
|
-- | -$3.78 | -- | -107.39% | $29.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PMVP
PMV Pharmaceuticals, Inc.
|
$1.07 | $7.60 | $56.9M | -- | $0.00 | 0% | -- |
|
ACRS
Aclaris Therapeutics, Inc.
|
$3.17 | $8.00 | $343.5M | -- | $0.00 | 0% | 23.30x |
|
AVIR
Atea Pharmaceuticals, Inc.
|
$4.60 | $7.67 | $359.4M | -- | $0.00 | 0% | 0.84x |
|
ORMP
Oramed Pharmaceuticals, Inc.
|
$3.30 | $3.25 | $131.3M | 3.29x | $0.25 | 7.58% | 68.69x |
|
PBYI
Puma Biotechnology, Inc.
|
$6.68 | $5.00 | $336.6M | 9.02x | $0.00 | 0% | 1.58x |
|
TIL
Instil Bio, Inc.
|
$8.88 | $29.00 | $60.2M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PMVP
PMV Pharmaceuticals, Inc.
|
0.76% | 2.154 | 1.25% | 10.50x |
|
ACRS
Aclaris Therapeutics, Inc.
|
1.83% | 2.641 | 1.09% | 3.92x |
|
AVIR
Atea Pharmaceuticals, Inc.
|
0.33% | 0.572 | 0.46% | 16.32x |
|
ORMP
Oramed Pharmaceuticals, Inc.
|
0.42% | -0.079 | 0.8% | 22.01x |
|
PBYI
Puma Biotechnology, Inc.
|
26.26% | 0.917 | 15.34% | 1.57x |
|
TIL
Instil Bio, Inc.
|
41.36% | 5.678 | 70.11% | 14.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PMVP
PMV Pharmaceuticals, Inc.
|
-$32K | -$22.5M | -50.85% | -51.97% | -- | -$19.8M |
|
ACRS
Aclaris Therapeutics, Inc.
|
$850K | -$17M | -102.07% | -103.93% | -516.79% | -$11M |
|
AVIR
Atea Pharmaceuticals, Inc.
|
-$104K | -$45.6M | -36.83% | -36.97% | -- | -$40.4M |
|
ORMP
Oramed Pharmaceuticals, Inc.
|
-$31K | -$2.4M | 27.4% | 27.49% | -225% | -$2M |
|
PBYI
Puma Biotechnology, Inc.
|
$42.3M | $9.6M | 23.32% | 38.49% | 17.57% | $9.7M |
|
TIL
Instil Bio, Inc.
|
-$12K | -$15M | -32.04% | -50.54% | -- | -$10.6M |
PMV Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns PMVP or ACRS?
Aclaris Therapeutics, Inc. has a net margin of -- compared to PMV Pharmaceuticals, Inc.'s net margin of -442.98%. PMV Pharmaceuticals, Inc.'s return on equity of -51.97% beat Aclaris Therapeutics, Inc.'s return on equity of -103.93%.
Company Gross Margin Earnings Per Share Invested Capital PMVPPMV Pharmaceuticals, Inc.-- -$0.40 $121.9M ACRSAclaris Therapeutics, Inc.25.77% -$0.12 $122.3M -
What do Analysts Say About PMVP or ACRS?
PMV Pharmaceuticals, Inc. has a consensus price target of $7.60, signalling upside risk potential of 610.28%. On the other hand Aclaris Therapeutics, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 152.37%. Given that PMV Pharmaceuticals, Inc. has higher upside potential than Aclaris Therapeutics, Inc., analysts believe PMV Pharmaceuticals, Inc. is more attractive than Aclaris Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMVPPMV Pharmaceuticals, Inc.6 0 0 ACRSAclaris Therapeutics, Inc.6 1 0 -
Is PMVP or ACRS More Risky?
PMV Pharmaceuticals, Inc. has a beta of 1.396, which suggesting that the stock is 39.573% more volatile than S&P 500. In comparison Aclaris Therapeutics, Inc. has a beta of 0.860, suggesting its less volatile than the S&P 500 by 13.979%.
-
Which is a Better Dividend Stock PMVP or ACRS?
PMV Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aclaris Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PMV Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Aclaris Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMVP or ACRS?
PMV Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Aclaris Therapeutics, Inc. quarterly revenues of $3.3M. PMV Pharmaceuticals, Inc.'s net income of -$21.1M is lower than Aclaris Therapeutics, Inc.'s net income of -$14.6M. Notably, PMV Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Aclaris Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PMV Pharmaceuticals, Inc. is -- versus 23.30x for Aclaris Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMVPPMV Pharmaceuticals, Inc.-- -- -- -$21.1M ACRSAclaris Therapeutics, Inc.23.30x -- $3.3M -$14.6M
-
Which has Higher Returns PMVP or AVIR?
Atea Pharmaceuticals, Inc. has a net margin of -- compared to PMV Pharmaceuticals, Inc.'s net margin of --. PMV Pharmaceuticals, Inc.'s return on equity of -51.97% beat Atea Pharmaceuticals, Inc.'s return on equity of -36.97%.
Company Gross Margin Earnings Per Share Invested Capital PMVPPMV Pharmaceuticals, Inc.-- -$0.40 $121.9M AVIRAtea Pharmaceuticals, Inc.-- -$0.53 $316.8M -
What do Analysts Say About PMVP or AVIR?
PMV Pharmaceuticals, Inc. has a consensus price target of $7.60, signalling upside risk potential of 610.28%. On the other hand Atea Pharmaceuticals, Inc. has an analysts' consensus of $7.67 which suggests that it could grow by 66.67%. Given that PMV Pharmaceuticals, Inc. has higher upside potential than Atea Pharmaceuticals, Inc., analysts believe PMV Pharmaceuticals, Inc. is more attractive than Atea Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMVPPMV Pharmaceuticals, Inc.6 0 0 AVIRAtea Pharmaceuticals, Inc.2 1 0 -
Is PMVP or AVIR More Risky?
PMV Pharmaceuticals, Inc. has a beta of 1.396, which suggesting that the stock is 39.573% more volatile than S&P 500. In comparison Atea Pharmaceuticals, Inc. has a beta of 0.239, suggesting its less volatile than the S&P 500 by 76.143%.
-
Which is a Better Dividend Stock PMVP or AVIR?
PMV Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atea Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PMV Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Atea Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMVP or AVIR?
PMV Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Atea Pharmaceuticals, Inc. quarterly revenues of --. PMV Pharmaceuticals, Inc.'s net income of -$21.1M is higher than Atea Pharmaceuticals, Inc.'s net income of -$42M. Notably, PMV Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Atea Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PMV Pharmaceuticals, Inc. is -- versus 0.84x for Atea Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMVPPMV Pharmaceuticals, Inc.-- -- -- -$21.1M AVIRAtea Pharmaceuticals, Inc.0.84x -- -- -$42M
-
Which has Higher Returns PMVP or ORMP?
Oramed Pharmaceuticals, Inc. has a net margin of -- compared to PMV Pharmaceuticals, Inc.'s net margin of -382.1%. PMV Pharmaceuticals, Inc.'s return on equity of -51.97% beat Oramed Pharmaceuticals, Inc.'s return on equity of 27.49%.
Company Gross Margin Earnings Per Share Invested Capital PMVPPMV Pharmaceuticals, Inc.-- -$0.40 $121.9M ORMPOramed Pharmaceuticals, Inc.0.65% $1.13 $203.2M -
What do Analysts Say About PMVP or ORMP?
PMV Pharmaceuticals, Inc. has a consensus price target of $7.60, signalling upside risk potential of 610.28%. On the other hand Oramed Pharmaceuticals, Inc. has an analysts' consensus of $3.25 which suggests that it could fall by -1.52%. Given that PMV Pharmaceuticals, Inc. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe PMV Pharmaceuticals, Inc. is more attractive than Oramed Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMVPPMV Pharmaceuticals, Inc.6 0 0 ORMPOramed Pharmaceuticals, Inc.0 0 0 -
Is PMVP or ORMP More Risky?
PMV Pharmaceuticals, Inc. has a beta of 1.396, which suggesting that the stock is 39.573% more volatile than S&P 500. In comparison Oramed Pharmaceuticals, Inc. has a beta of 1.342, suggesting its more volatile than the S&P 500 by 34.249%.
-
Which is a Better Dividend Stock PMVP or ORMP?
PMV Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oramed Pharmaceuticals, Inc. offers a yield of 7.58% to investors and pays a quarterly dividend of $0.25 per share. PMV Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oramed Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMVP or ORMP?
PMV Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Oramed Pharmaceuticals, Inc. quarterly revenues of --. PMV Pharmaceuticals, Inc.'s net income of -$21.1M is lower than Oramed Pharmaceuticals, Inc.'s net income of $48.4M. Notably, PMV Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oramed Pharmaceuticals, Inc.'s PE ratio is 3.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PMV Pharmaceuticals, Inc. is -- versus 68.69x for Oramed Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMVPPMV Pharmaceuticals, Inc.-- -- -- -$21.1M ORMPOramed Pharmaceuticals, Inc.68.69x 3.29x -- $48.4M
-
Which has Higher Returns PMVP or PBYI?
Puma Biotechnology, Inc. has a net margin of -- compared to PMV Pharmaceuticals, Inc.'s net margin of 16.24%. PMV Pharmaceuticals, Inc.'s return on equity of -51.97% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.
Company Gross Margin Earnings Per Share Invested Capital PMVPPMV Pharmaceuticals, Inc.-- -$0.40 $121.9M PBYIPuma Biotechnology, Inc.77.65% $0.17 $156.3M -
What do Analysts Say About PMVP or PBYI?
PMV Pharmaceuticals, Inc. has a consensus price target of $7.60, signalling upside risk potential of 610.28%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $5.00 which suggests that it could fall by -25.15%. Given that PMV Pharmaceuticals, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe PMV Pharmaceuticals, Inc. is more attractive than Puma Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMVPPMV Pharmaceuticals, Inc.6 0 0 PBYIPuma Biotechnology, Inc.0 1 0 -
Is PMVP or PBYI More Risky?
PMV Pharmaceuticals, Inc. has a beta of 1.396, which suggesting that the stock is 39.573% more volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.221, suggesting its more volatile than the S&P 500 by 22.056%.
-
Which is a Better Dividend Stock PMVP or PBYI?
PMV Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PMV Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMVP or PBYI?
PMV Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. PMV Pharmaceuticals, Inc.'s net income of -$21.1M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, PMV Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 9.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PMV Pharmaceuticals, Inc. is -- versus 1.58x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMVPPMV Pharmaceuticals, Inc.-- -- -- -$21.1M PBYIPuma Biotechnology, Inc.1.58x 9.02x $54.5M $8.8M
-
Which has Higher Returns PMVP or TIL?
Instil Bio, Inc. has a net margin of -- compared to PMV Pharmaceuticals, Inc.'s net margin of --. PMV Pharmaceuticals, Inc.'s return on equity of -51.97% beat Instil Bio, Inc.'s return on equity of -50.54%.
Company Gross Margin Earnings Per Share Invested Capital PMVPPMV Pharmaceuticals, Inc.-- -$0.40 $121.9M TILInstil Bio, Inc.-- -$2.01 $205.3M -
What do Analysts Say About PMVP or TIL?
PMV Pharmaceuticals, Inc. has a consensus price target of $7.60, signalling upside risk potential of 610.28%. On the other hand Instil Bio, Inc. has an analysts' consensus of $29.00 which suggests that it could grow by 226.58%. Given that PMV Pharmaceuticals, Inc. has higher upside potential than Instil Bio, Inc., analysts believe PMV Pharmaceuticals, Inc. is more attractive than Instil Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMVPPMV Pharmaceuticals, Inc.6 0 0 TILInstil Bio, Inc.1 3 0 -
Is PMVP or TIL More Risky?
PMV Pharmaceuticals, Inc. has a beta of 1.396, which suggesting that the stock is 39.573% more volatile than S&P 500. In comparison Instil Bio, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PMVP or TIL?
PMV Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Instil Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PMV Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Instil Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMVP or TIL?
PMV Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Instil Bio, Inc. quarterly revenues of --. PMV Pharmaceuticals, Inc.'s net income of -$21.1M is lower than Instil Bio, Inc.'s net income of -$13.6M. Notably, PMV Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Instil Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PMV Pharmaceuticals, Inc. is -- versus -- for Instil Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMVPPMV Pharmaceuticals, Inc.-- -- -- -$21.1M TILInstil Bio, Inc.-- -- -- -$13.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 5.01% over the past day.
Buy
90
TCMD alert for Feb 19
Tactile Systems Technology, Inc. [TCMD] is down 9.98% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 2.56% over the past day.
